2024
Randomized Controlled Trial of Integrated Adherence Support to Improve Treatment Outcomes in Patients With Drug-resistant Tuberculosis and HIV
Perumal R, Wolf A, Zelnick J, Friedland G, Amico R, Daftary A, Boodhram R, Padayatchi N, Naidoo K, O'Donnell M. Randomized Controlled Trial of Integrated Adherence Support to Improve Treatment Outcomes in Patients With Drug-resistant Tuberculosis and HIV. 2024, a6948-a6948. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6948.Peer-Reviewed Original ResearchStigma in People With Multidrug-resistant Tuberculosis and HIV in South Africa
Reis K, Wolf A, Perumal R, Zulu M, Seepamore B, Guzman K, Ross J, Nyilana H, Cheung Y, Friedland G, Naidoo K, Zelnick J, Daftary A, O'Donnell M, Amico K. Stigma in People With Multidrug-resistant Tuberculosis and HIV in South Africa. 2024, a4881-a4881. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a4881.Peer-Reviewed Original ResearchLatent Class Analysis of Structural Factors Reveals Subgroups With Differential Adherence to Bedaquiline and Antiretroviral Therapy Among People Living With HIV and Drug Resistant Tuberculosis
Guzman K, Wolf A, Perumal R, Cummings M, Zulu M, Zelnick J, Friedland G, Amico K, Reis K, Cheung Y, Daftary A, Seepamore B, Naidoo K, ODonnell M. Latent Class Analysis of Structural Factors Reveals Subgroups With Differential Adherence to Bedaquiline and Antiretroviral Therapy Among People Living With HIV and Drug Resistant Tuberculosis. 2024, a4884-a4884. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a4884.Peer-Reviewed Original ResearchBrief Report: Differentiated Service Delivery Framework for People With Multidrug-Resistant Tuberculosis and HIV Coinfection
Reis K, Wolf A, Perumal R, Seepamore B, Guzman K, Ross J, Cheung Y, Amico K, Brust J, Padayatchi N, Friedland G, Naidoo K, Daftary A, Zelnick J, O'Donnell M. Brief Report: Differentiated Service Delivery Framework for People With Multidrug-Resistant Tuberculosis and HIV Coinfection. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2024, 96: 34-39. PMID: 38323838, PMCID: PMC11300702, DOI: 10.1097/qai.0000000000003394.Peer-Reviewed Original ResearchMultidrug-resistant tuberculosisDifferentiated service deliveryAntiretroviral therapyElectronic dose monitoring devicesAntiretroviral therapy adherenceMultidrug-resistant tuberculosis treatmentDifferentiated service delivery modelsHIV co-infectionTreatment courseCumulative adherenceTreatment challengesCo-infectionBedaquilineTreatment completionFocus groupsMedication adherenceHIVTreatmentPatterns of medication adherenceAdherenceTuberculosisSubpopulationsHIV/AIDSTreatment stageStage-specific
2023
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial
Ross J, Perumal R, Wolf A, Zulu M, Guzman K, Seepamore B, Reis K, Nyilana H, Hlathi S, Narasimmulu R, Cheung Y, Amico K, Friedland G, Daftary A, Zelnick J, Naidoo K, O’Donnell M. Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial. Trials 2023, 24: 776. PMID: 38037105, PMCID: PMC10691086, DOI: 10.1186/s13063-023-07520-9.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisAdherence support interventionsAntiretroviral therapyTreatment regimensAdherence supportPrimary outcomeTreatment supportPsychosocial supportMDR-TB treatment regimensUndetectable HIV viral loadSupport interventionsIntegrase strand transfer inhibitorsAdherence support strategiesComposite clinical outcomeMDR-TB regimensNegative TB culturesCombination antiretroviral therapyComposite primary outcomeHIV treatment outcomesHIV viral loadDrug-resistant tuberculosisStandard of careNew treatment regimensDifferentiated service deliveryStrand transfer inhibitorsBuilding an Infectious Disease Diversity, Equity, and Antiracism (ID2EA) Curriculum: A Single Center's Experience and Reflections
Gleeson S, Zapata H, Bathgate M, Emu B, Frederick J, Friedland G, Golden M, Meyer J, Radin J, Sideleau R, Shaw A, Shenoi S, Trubin P, Virata M, Barakat L, Desruisseaux M. Building an Infectious Disease Diversity, Equity, and Antiracism (ID2EA) Curriculum: A Single Center's Experience and Reflections. Clinical Infectious Diseases 2023, 77: 703-710. PMID: 37078888, DOI: 10.1093/cid/ciad236.Peer-Reviewed Original ResearchConceptsEducational activitiesHealthcare inequitiesInfectious Diseases SectionSingle-center experienceCoronavirus disease 2019 (COVID-19) pandemicDisease 2019 pandemicMixed-methods assessmentLearning objectivesPilot curriculumEducational trainingCurriculumCenter experienceLong-term behavioral changesProgram outcomesDisease sectionDisease diversityPhysician perspectivesResponse rateHealth disparitiesYale SchoolInequitiesAntiracismBehavioral changesRacismEquity
2022
Community-based referral for tuberculosis preventive therapy is effective for treatment completion
Shenoi S, Kyriakides T, Dokubo E, Guddera V, Vranken P, Desai M, Friedland G, Moll A. Community-based referral for tuberculosis preventive therapy is effective for treatment completion. PLOS Global Public Health 2022, 2: e0001269. PMID: 36962910, PMCID: PMC10021376, DOI: 10.1371/journal.pgph.0001269.Peer-Reviewed Original ResearchTreatment completionCommunity-based identificationPreventive therapyIndependent predictorsGovernment primary care clinicsMedian age 35 yearsCommunity-based referralsHigher treatment completionMedian CD4 countTB preventive therapyTB endemic regionsTuberculosis preventive therapyComparison groupPrimary care clinicsClinic-based careAge 35 yearsCBR groupTeam of nursesSix-month courseMedian CD4Oral isoniazidCD4 countHIV careNight sweatsCare clinicsCorrection to: Experiences with Telemedicine for HIV Care During the COVID-19 Pandemic: A Mixed-Methods Study
Harsono D, Deng Y, Chung S, Barakat LA, Friedland G, Meyer JP, Porter E, Villanueva M, Wolf MS, Yager JE, Edelman EJ. Correction to: Experiences with Telemedicine for HIV Care During the COVID-19 Pandemic: A Mixed-Methods Study. AIDS And Behavior 2022, 27: 2054-2054. PMID: 36318433, PMCID: PMC9628372, DOI: 10.1007/s10461-022-03907-y.Peer-Reviewed Original ResearchLong-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH)
Tuan JJ, Zapata H, Barakat L, Andrews L, Behnegar A, Kim YW, Kayani J, Mutic S, Ryall L, Turcotte B, Critch-Gilfillan T, Zhao M, Salahuddin S, Gupta S, Sutton R, Friedland G, Emu B, Ogbuagu O. Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH). BMC Infectious Diseases 2022, 22: 744. PMID: 36131232, PMCID: PMC9491266, DOI: 10.1186/s12879-022-07737-0.Peer-Reviewed Original ResearchConceptsT cell responsesAnti-spike IgGVisit 3SARS-CoV-2Older PWHVisit 2Immune responseSingle-center longitudinal observational studyVirus-specific T cell responsesVaccine-induced humoral immunityLong-term protective immunityT cell immune responsesOlder peopleMedian age 61RBD IgG levelsPrimary study outcomeCOVID-19 vaccinationImmune response evaluationLongitudinal observational studyCOVID-19 vaccineWilcoxon signed-rank testBNT162b2 boosterBNT162b2 vaccinationCD8 responsesDetectable CD4Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/AIDS
O'Donnell MR, Padayatchi N, Wolf A, Zelnick J, Daftary A, Orrell C, Nimmo C, Baldwin M, Boodhram R, Maharaj B, Amico KR, Naidoo K, Friedland G. Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/AIDS. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2022, 90: 325-332. PMID: 35195572, PMCID: PMC11077859, DOI: 10.1097/qai.0000000000002940.Peer-Reviewed Original ResearchConceptsMDR-TB treatment outcomesResistance-associated variantsTreatment outcomesAntiretroviral therapyMDR-TBART adherenceMultidrug-resistant tuberculosis treatmentHIV treatment outcomesProspective cohort studyMultidrug-resistant tuberculosisEnd of treatmentTreatment of patientsSuccessful treatment outcomeElectronic dose monitoring devicesHIV/AIDSCohort studyClinical outcomesMultivariable analysisNovel regimensMedication adherenceAdherence thresholdTuberculosis treatmentTreatment completionLow adherenceDose monitoringAdherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis
Bateman M, Wolf A, Chimukangara B, Brust JCM, Lessells R, Amico R, Boodhram R, Singh N, Orrell C, Friedland G, Naidoo K, Padayatchi N, O’Donnell MR. Adherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis. Clinical Infectious Diseases 2022, 75: 1489-1496. PMID: 35352097, PMCID: PMC9617578, DOI: 10.1093/cid/ciac232.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisHuman immunodeficiency virusMDR-TB treatmentART adherenceART resistanceHuman immunodeficiency virus/AIDSEmergent resistanceStandard of careResource-limited settingsTB regimensAntiretroviral resistanceHIV RNAProspective cohortMedication adherenceImmunodeficiency virusPoor outcomeShort followAdherence thresholdCopies/Treatment outcomesDose monitoringResistance mutationsResistance testingPublic hospitalsLinear associationManaging COVID-19 going forward—the lessons from history
Bucala R, Friedland G, Snowden F. Managing COVID-19 going forward—the lessons from history. QJM 2022, 115: 649-650. PMID: 35262710, PMCID: PMC9383561, DOI: 10.1093/qjmed/hcac065.Peer-Reviewed Original ResearchExperiences with Telemedicine for HIV Care During the COVID-19 Pandemic: A Mixed-Methods Study
Harsono D, Deng Y, Chung S, Barakat LA, Friedland G, Meyer JP, Porter E, Villanueva M, Wolf MS, Yager JE, Edelman EJ. Experiences with Telemedicine for HIV Care During the COVID-19 Pandemic: A Mixed-Methods Study. AIDS And Behavior 2022, 26: 2099-2111. PMID: 35064390, PMCID: PMC8782707, DOI: 10.1007/s10461-021-03556-7.Peer-Reviewed Original ResearchConceptsHIV careRe-engage patientsMixed-methods studyCare team membersRoutine clinical experienceCOVID-19 pandemicBenefits of telemedicineHIV clinicTelemedicine visitsTelemedicine appointmentsReimbursement concernsClinical experienceClinical staffCareAppropriate billingPatientsPWHTelemedicinePatient remote monitoringReimbursement methodsPandemicHIVClinicVisits
2020
759. Where can we find active TB? Case finding at community sites and alcohol based venues (ABVs) in rural South Africa
Choi K, Shenoi S, Moll A, Friedland G. 759. Where can we find active TB? Case finding at community sites and alcohol based venues (ABVs) in rural South Africa. Open Forum Infectious Diseases 2020, 7: s426-s426. PMCID: PMC7778049, DOI: 10.1093/ofid/ofaa439.949.Peer-Reviewed Original ResearchAlcohol Use Disorders Identification TestHazardous alcohol useActive TBTB casesAlcohol useCase detectionOlder ageMean AUDITActive TB diseaseUseful adjunctive strategyPrimary care clinicsHIV rapid testsCommunity health workersTuberculosis case detectionResource limited settingsCases of TBDisorders Identification TestSubstance abuse servicesTB diseaseRandom glucoseBlood pressureMedian ageCare clinicsAdjunctive strategiesRisk factorsTB and women: a call to action
Daftary A, Furin J, Zelnick J, Venkatesan N, Steingart K, Smelyanskaya M, Seepamore B, Schoeman I, Reid M, Padayatchi N, O Donnell M, Mistry N, McKenna L, Mahbub T, Macdonald H, Loveday M, Law S, LaCourse S, Jaramillo E, Janssen R, Hirsch-Moverman Y, Friedland G, Creswell J, Chorna Y, Chikovore J, Brigden G, Boffa J, Boehme C, Atre S, Amico K, Acquah R, Engel N. TB and women: a call to action. The International Journal Of Tuberculosis And Lung Disease 2020, 24: 1312-1315. PMID: 33317679, DOI: 10.5588/ijtld.20.0414.Peer-Reviewed Original ResearchPreventing COVID-19 Collateral Damage
Shepherd J, Friedland G. Preventing COVID-19 Collateral Damage. Clinical Infectious Diseases 2020, 71: 1564-1567. PMID: 32544952, PMCID: PMC7337641, DOI: 10.1093/cid/ciaa772.Peer-Reviewed Original ResearchConfronting Another Pandemic: Lessons from HIV can Inform Our COVID-19 Response
Edelman EJ, Aoun-Barakat L, Villanueva M, Friedland G. Confronting Another Pandemic: Lessons from HIV can Inform Our COVID-19 Response. AIDS And Behavior 2020, 24: 1977-1979. PMID: 32399798, PMCID: PMC7215127, DOI: 10.1007/s10461-020-02908-z.Peer-Reviewed Original ResearchDoes Routinely Provided Directly Observed Treatment Improve Adherence to Bedaquiline in Patients with Drug-Resistant TB HIV in South Africa (Praxis Study)?
Wolf A, Braunlin H, Amico K, Zelnick J, Boodhram R, Orrell C, Daftary A, Friedland G, Padayatchi N, O'Donnell M. Does Routinely Provided Directly Observed Treatment Improve Adherence to Bedaquiline in Patients with Drug-Resistant TB HIV in South Africa (Praxis Study)? 2020, a2690-a2690. DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2690.Peer-Reviewed Original ResearchBedaquiline Adherence Mediates Sputum TB Culture Conversion in MDR/XDR-TB Patients Co-Infected with HIV
Mudd J, Wolf A, Zelnick J, Boodhram R, Orrell C, Daftary A, Friedland G, Padayatchi N, O'Donnell M. Bedaquiline Adherence Mediates Sputum TB Culture Conversion in MDR/XDR-TB Patients Co-Infected with HIV. 2020, a2691-a2691. DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2691.Peer-Reviewed Original Research
2019
Opportunities for community health workers to contribute to global efforts to end tuberculosis
Sinha P, Shenoi SV, Friedland GH. Opportunities for community health workers to contribute to global efforts to end tuberculosis. Global Public Health 2019, 15: 474-484. PMID: 31516079, PMCID: PMC7028491, DOI: 10.1080/17441692.2019.1663361.Peer-Reviewed Original Research